Progress in natural compounds/siRNA co-delivery employing nanovehicles for cancer therapy

Ashrafizadeh, Milad and Zarrabi, Ali and Hushmandi, Kiavash and Hashemi, Farid and Rahmani Moghadam, Ebrahim and Raei, Mehdi and Kalantari, Mahshad and Tavakol, Shima and Mohammadinejad, Reza and Najafi, Masoud and Tay, Franklin R. and Makvandi, Pooyan (2020) Progress in natural compounds/siRNA co-delivery employing nanovehicles for cancer therapy. ACS Combinatorial Science, 22 (12). pp. 669-700. ISSN 2156-8952 (Print) 2156-8944 (Online)

Full text not available from this repository. (Request a copy)


Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, co-delivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.
Item Type: Article
Uncontrolled Keywords: anticancer therapy; chemotherapy; co-delivery platforms; nanocarriers; natural products; small interfering RNA
Divisions: Faculty of Engineering and Natural Sciences
Sabancı University Nanotechnology Research and Application Center
Depositing User: Ali Zarrabi
Date Deposited: 04 Aug 2023 16:22
Last Modified: 04 Aug 2023 16:22

Actions (login required)

View Item
View Item